NASDAQ:VRAX Virax Biolabs Group (VRAX) Stock Price, News & Analysis $2.38 -0.06 (-2.46%) Closing price 03:58 PM EasternExtended Trading$2.38 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings About Virax Biolabs Group Stock (NASDAQ:VRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virax Biolabs Group alerts:Sign Up Key Stats Today's Range$2.38▼$2.6050-Day Range$2.31▼$3.8952-Week Range$2.14▼$21.75Volume13,420 shsAverage Volume1.04 million shsMarket Capitalization$1.90 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection and diagnosis of viral diseases. The company develops and commercializes diagnostic technologies intended to help identify infections and assess immune responses to viral pathogens. Its portfolio includes molecular diagnostic products and immune-profiling technologies designed to measure T-cell responses to specific viruses. These products are intended for use by healthcare providers, laboratories and other organizations involved in infectious-disease testing and monitoring. Virax Biolabs is headquartered in the United Kingdom and has pursued international commercialization and distribution opportunities for its diagnostic products. The company became publicly traded on the Nasdaq under the symbol VRAX in 2022. James Foster has served as the company’s chief executive officer and chairman.AI Generated. May Contain Errors. Read More Virax Biolabs Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreVRAX MarketRank™: Virax Biolabs Group scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingVirax Biolabs Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialVirax Biolabs Group has a consensus price target of $25.00, representing about 945.2% upside from its current price of $2.39.Amount of Analyst CoverageVirax Biolabs Group has only been the subject of 1 research reports in the past 90 days.Read more about Virax Biolabs Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioVirax Biolabs Group has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Virax Biolabs Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.97% of the float of Virax Biolabs Group has been sold short.Short Interest Ratio / Days to CoverVirax Biolabs Group has a short interest ratio ("days to cover") of 0.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virax Biolabs Group has recently increased by 52.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVirax Biolabs Group does not currently pay a dividend.Dividend GrowthVirax Biolabs Group does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentVirax Biolabs Group has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Virax Biolabs Group this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Virax Biolabs Group insiders have not sold or bought any company stock.Percentage Held by Insiders45.10% of the stock of Virax Biolabs Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.61% of the stock of Virax Biolabs Group is held by institutions.Read more about Virax Biolabs Group's insider trading history. Receive VRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRAX Stock News HeadlinesVirax Biolabs Group (NASDAQ:VRAX) Stock Price Up 8.2% - Should You Buy?September 23 at 3:06 AM | americanbankingnews.comVirax Biolabs Expands ATM Share Offering With New SEC FilingSeptember 4, 2026 | tipranks.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 25 at 1:00 AM | The Oxford Club (Ad)Virax Biolabs Shareholders Approve Major Capital Increase but Reject Governance OverhaulAugust 26, 2026 | tipranks.comJoin Virax’s Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial ExecutionAugust 20, 2026 | usatoday.comVirax Biolabs Calls August 14 EGM to Approve Major Share Capital IncreaseAugust 2, 2026 | theglobeandmail.comRedChip Companies, Inc.: Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TVJuly 20, 2026 | finanznachrichten.deVirax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 ReportJuly 17, 2026 | tipranks.comSee More Headlines VRAX Stock Analysis - Frequently Asked Questions How have VRAX shares performed this year? Virax Biolabs Group's stock was trading at $8.6450 on January 1st, 2026. Since then, VRAX stock has decreased by 72.3% and is now trading at $2.3920. How were Virax Biolabs Group's earnings last quarter? Virax Biolabs Group Limited (NASDAQ:VRAX) issued its quarterly earnings results on Friday, July, 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.75) by $1.56. The company earned $0.01 million during the quarter, compared to analyst estimates of $0 million. When did Virax Biolabs Group's stock split? Virax Biolabs Group's stock reverse split on the morning of Friday, June 26th 2026.The 1-25 reverse split was announced on Wednesday, June 24th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 26th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Virax Biolabs Group IPO? Virax Biolabs Group (VRAX) raised $7 million in an initial public offering (IPO) on Thursday, July 21st 2022. The company issued 1,400,000 shares at a price of $5.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Virax Biolabs Group? Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virax Biolabs Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virax Biolabs Group investors own include Plug Power (PLUG), GeoVax Labs (GOVX), Fortress Biotech (FBIO), KALA BIO (KALA), Comtech Telecommunications (CMTL), FuelCell Energy (FCEL) and Lipocine (LPCN). Company Calendar Last Earnings7/03/2026Today9/25/2026Next Earnings (Estimated)12/02/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VRAX's financial health is in the Yellow zone, according to TradeSmith. VRAX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:VRAX CIK1885827 Webviraxbiolabs.com Phone44-0-20-7788-7414FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Price Target for Virax Biolabs Group$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+950.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.97 Quick Ratio9.97 Sales & Book Value Annual Sales$10 thousand Price / Sales190.40 Cash FlowN/A Price / Cash FlowN/A Book Value$42.23 per share Price / Book0.06Miscellaneous Outstanding Shares800,000Free Float438,000Market Cap$1.90 million OptionableNot Optionable Beta1.37 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:VRAX) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
